Peer-reviewed veterinary case report
Dexamethasone and cyclosporine eye drops for dog eye disease treatment
By Balicki, I et al.·Published in Polish journal of veterinary sciences·2021·Department and Clinic of Animal Surgery·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical study on the application of dexamethasone and cyclosporine/dimethyl sulfoxide combination eye drops in the initial therapy of chronic superficial keratitis in dogs.
- Species:
- dog
Plain-English summary
A group of 41 dogs aged 2 to 9 years with chronic superficial keratitis (CSK), a condition affecting the eyes, were treated with a combination of dexamethasone and cyclosporine/dimethyl sulfoxide eye drops. After five weeks of treatment, the dogs showed a significant reduction in eye inflammation and neovascularization (new blood vessel growth) in both eyes. While the treatment helped reduce inflammation, it did not stop the progression of pigmentation in many cases. Overall, this combination of eye drops appears to be an effective initial therapy for managing CSK in dogs.
People also search for: dog eye problems treatment · chronic superficial keratitis in dogs · dexamethasone eye drops for dogs
Abstract
PURPOSE: To assess the initial therapy of chronic superficial keratitis (CSK) in dogs with the use of dexamethasone and cyclosporine/ dimethyl sulfoxide combination eye drops. METHODS: The study was conducted on 41 dogs - 16 males and 25 females, aged 2 to 9 years, diagnosed with CSK. The disease was treated with two kinds of eye drops containing 0.1% dexamethasone and 0.75% cyclosporine in combination with 30% DMSO, administered three times a day. Prior to the treatment and after 5 weeks of therapy, depigmentation of the third eyelid margin, corneal neovascularization and pigmentation were assessed. The percentage of the corneal surface afflicted with inflammatory processes was calculated with the use of IsoCalc.com's Get Area software for CorelDRAW12. RESULTS: The administered therapy resulted in a significant decrease in the mean number of quadrants affected by corneal neovascularization in the right eye from 2.63 prior to treatment to 0.24 after treatment (p⟨0.001), and the left eye from 2.66 to 0.59 (p⟨0.001), respectively. Mean corneal surface afflicted with inflammatory processes was statistically significantly reduced from 53.5% to 26.3% (p⟨0.001) in the case of right corneas, and from 54.5% to 30.2% (p⟨0.001) in the case of left corneas. Of 77 corneas diagnosed with pigmentation, pigmentation reduction was observed in 54 and pigmentation increase in 27. CONCLUSIONS: Using dexamethasone and cyclosporine/DMSO combination eye drops proved to be a viable initial therapy against CSK, which facilitates reduction of inflammatory processes and neovascularization atrophy, but in many cases does not inhibit the progress of pigmentation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34730300/